S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33
S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33
S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33
S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33
NYSE:BIO

Bio-Rad Laboratories Stock Forecast, Price & News

$802.96
+5.62 (+0.70 %)
(As of 09/24/2021 12:00 AM ET)
Add
Compare
Today's Range
$790.64
$804.65
50-Day Range
$663.05
$825.77
52-Week Range
$491.58
$832.70
Volume135,725 shs
Average Volume160,282 shs
Market Capitalization$23.91 billion
P/E Ratio5.99
Dividend YieldN/A
Beta0.85
30 days | 90 days | 365 days | Advanced Chart
Receive BIO News and Ratings via Email

Sign-up to receive the latest news and ratings for Bio-Rad Laboratories and its competitors with MarketBeat's FREE daily newsletter.


Bio-Rad Laboratories logo

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc. engages in the development and production of specialty chemicals used in biochemical, pharmaceutical, and other life science research applications. It operates through the Life Sciences and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets reagents, apparatus, and laboratory instruments. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, and test kits. The company was founded by David S. Schwartz and Alice N. Schwartz in 1952 and is headquartered in Hercules, CA.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous

Social Links


MarketRank

Overall MarketRank

2.26 out of 5 stars

Medical Sector

290th out of 1,351 stocks

Analytical Instruments Industry

6th out of 30 stocks

Analyst Opinion: 1.5Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 4.2Valuation: 1.3 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Bio-Rad Laboratories (NYSE:BIO) Frequently Asked Questions

Is Bio-Rad Laboratories a buy right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Bio-Rad Laboratories in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Bio-Rad Laboratories stock.
View analyst ratings for Bio-Rad Laboratories
or view top-rated stocks.

What stocks does MarketBeat like better than Bio-Rad Laboratories?

Wall Street analysts have given Bio-Rad Laboratories a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Bio-Rad Laboratories wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Bio-Rad Laboratories?

Bio-Rad Laboratories saw a decline in short interest during the month of August. As of August 31st, there was short interest totaling 533,000 shares, a decline of 20.3% from the August 15th total of 668,400 shares. Based on an average daily volume of 112,400 shares, the days-to-cover ratio is presently 4.7 days. Currently, 2.5% of the company's shares are sold short.
View Bio-Rad Laboratories' Short Interest
.

When is Bio-Rad Laboratories' next earnings date?

Bio-Rad Laboratories is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for Bio-Rad Laboratories
.

How were Bio-Rad Laboratories' earnings last quarter?

Bio-Rad Laboratories, Inc. (NYSE:BIO) issued its earnings results on Wednesday, July, 28th. The medical research company reported $3.54 earnings per share for the quarter, beating the consensus estimate of $2.66 by $0.88. The medical research company had revenue of $715.93 million for the quarter, compared to analysts' expectations of $610.40 million. Bio-Rad Laboratories had a net margin of 140.48% and a trailing twelve-month return on equity of 4.65%.
View Bio-Rad Laboratories' earnings history
.

How has Bio-Rad Laboratories' stock price been impacted by Coronavirus?

Bio-Rad Laboratories' stock was trading at $345.79 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, BIO shares have increased by 132.2% and is now trading at $802.96.
View which stocks have been most impacted by COVID-19
.

What guidance has Bio-Rad Laboratories issued on next quarter's earnings?

Bio-Rad Laboratories issued an update on its FY 2021 earnings guidance on Thursday, August, 5th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $2.77 billion-$2.78 billion, compared to the consensus revenue estimate of $2.71 billion.

What price target have analysts set for BIO?

3 Wall Street analysts have issued 1 year price objectives for Bio-Rad Laboratories' stock. Their forecasts range from $675.00 to $930.00. On average, they anticipate Bio-Rad Laboratories' share price to reach $770.00 in the next twelve months. This suggests that the stock has a possible downside of 4.1%.
View analysts' price targets for Bio-Rad Laboratories
or view top-rated stocks among Wall Street analysts.

Who are Bio-Rad Laboratories' key executives?

Bio-Rad Laboratories' management team includes the following people:
  • Norman D. Schwartz, Chairman, President & Chief Executive Officer
  • Andrew J. Last, Chief Operating Officer & Executive Vice President
  • Ilan Daskal, Chief Financial Officer & Executive Vice President (LinkedIn Profile)
  • Timothy S. Ernst, Secretary, Executive VP & General Counsel
  • Dara Grantham Wright, EVP & President-Clinical Diagnostics Group

What is Norman Schwartz's approval rating as Bio-Rad Laboratories' CEO?

325 employees have rated Bio-Rad Laboratories CEO Norman Schwartz on Glassdoor.com. Norman Schwartz has an approval rating of 84% among Bio-Rad Laboratories' employees.

What other stocks do shareholders of Bio-Rad Laboratories own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Bio-Rad Laboratories investors own include BioMarin Pharmaceutical (BMRN), Incyte (INCY), Puma Biotechnology (PBYI), AbbVie (ABBV), NVIDIA (NVDA), Broadcom (AVGO), Johnson & Johnson (JNJ), Advanced Micro Devices (AMD), Alibaba Group (BABA) and Intel (INTC).

What is Bio-Rad Laboratories' stock symbol?

Bio-Rad Laboratories trades on the New York Stock Exchange (NYSE) under the ticker symbol "BIO."

Who are Bio-Rad Laboratories' major shareholders?

Bio-Rad Laboratories' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (7.66%), BlackRock Inc. (6.18%), FMR LLC (5.40%), State Street Corp (3.27%), Alliancebernstein L.P. (1.76%) and Marshall Wace LLP (1.46%). Company insiders that own Bio-Rad Laboratories stock include Annette Tumolo, Giovanni Magni, Ilan Daskal, James R Stark, Michael Crowley, Ronald W Hutton and Timothy S Ernst.
View institutional ownership trends for Bio-Rad Laboratories
.

Which institutional investors are selling Bio-Rad Laboratories stock?

BIO stock was sold by a variety of institutional investors in the last quarter, including American Century Companies Inc., Natixis, Marshall Wace LLP, Invesco Ltd., BlackRock Inc., Nuveen Asset Management LLC, Armistice Capital LLC, and Federated Hermes Inc.. Company insiders that have sold Bio-Rad Laboratories company stock in the last year include Annette Tumolo, Ilan Daskal, Michael Crowley, and Timothy S Ernst.
View insider buying and selling activity for Bio-Rad Laboratories
or view top insider-selling stocks.

Which institutional investors are buying Bio-Rad Laboratories stock?

BIO stock was acquired by a variety of institutional investors in the last quarter, including Franklin Resources Inc., FMR LLC, Bank of New York Mellon Corp, Alliancebernstein L.P., Credit Suisse AG, Exane Asset Management, Intermede Investment Partners Ltd, and Balyasny Asset Management LLC.
View insider buying and selling activity for Bio-Rad Laboratories
or or view top insider-buying stocks.

How do I buy shares of Bio-Rad Laboratories?

Shares of BIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Bio-Rad Laboratories' stock price today?

One share of BIO stock can currently be purchased for approximately $802.96.

How much money does Bio-Rad Laboratories make?

Bio-Rad Laboratories has a market capitalization of $23.91 billion and generates $2.55 billion in revenue each year. The medical research company earns $3.81 billion in net income (profit) each year or $10.52 on an earnings per share basis.

How many employees does Bio-Rad Laboratories have?

Bio-Rad Laboratories employs 8,000 workers across the globe.

Does Bio-Rad Laboratories have any subsidiaries?

The following companies are subsidiares of Bio-Rad Laboratories: BIO-RAD spol. s r.o., Bio-Metrics (U.K.) Limited, Bio-Metrics Limited, Bio-Metrics Properties Limited, Bio-Rad (France), Bio-Rad (Shanghai) Life Science Research & Development Co. Ltd., Bio-Rad 1, Bio-Rad AbD Serotec GmbH, Bio-Rad AbD Serotec Ltd, Bio-Rad China Ltd., Bio-Rad Denmark ApS, Bio-Rad Europe GmbH, Bio-Rad Export LLC, Bio-Rad France, Bio-Rad France Holding, Bio-Rad Germany Holding GmbH, Bio-Rad Haifa Ltd., Bio-Rad Holdings LLC, Bio-Rad Hungary Trading LLC, Bio-Rad IHC Europe GmbH, Bio-Rad Innovations, Bio-Rad Korea Ltd., Bio-Rad Laboratories (Canada) Limited, Bio-Rad Laboratories (India) Private Limited, Bio-Rad Laboratories (Israel) Inc., Bio-Rad Laboratories (Pty) Ltd, Bio-Rad Laboratories (Shanghai) Co. Ltd., Bio-Rad Laboratories (Singapore) Pte Ltd, Bio-Rad Laboratories AB, Bio-Rad Laboratories AG, Bio-Rad Laboratories B.V., Bio-Rad Laboratories Ges.m.b.H., Bio-Rad Laboratories GmbH, Bio-Rad Laboratories K.K., Bio-Rad Laboratories Limited, Bio-Rad Laboratories Logistik GmbH, Bio-Rad Laboratories Ltd., Bio-Rad Laboratories M.EPE, Bio-Rad Laboratories NV, Bio-Rad Laboratories Pty Ltd, Bio-Rad Laboratories S.A., Bio-Rad Laboratories S.r.l., Bio-Rad Laboratories SAS, Bio-Rad Laboratories-Aparelhos e Reagentes para Laboratórios Lda, Bio-Rad Laboratorii OOO, Bio-Rad Laboratórios Brasil Ltda., Bio-Rad Luxembourg S.à r.l., Bio-Rad Medical Diagnostics GmbH, Bio-Rad Middle East FZ-LLC, Bio-Rad Norway AS, Bio-Rad Pacific Limited, Bio-Rad Polska Sp. z o.o., Bio-Rad QL Inc., Bio-Rad S.A., Bio-Rad Services France, Bio-Rad Services UK Limited, Blackhawk Biosystems, Bridger Technologies Inc., Celsee, DiaMed, DiaMed (G.B.) Ltd, DiaMed (Schweiz) GmbH, DiaMed Benelux NV, DiaMed Diagnostika Deutschland GmbH, DiaMed Fennica Oy, DiaMed France SA, DiaMed Holding AG, DiaMed Holding GmbH, DiaMed Latino-América S.A., DiaMed S.E.A. Limited, DiaMed Österreich GmbH, Distribudora de Analítica para la Medicina Ibérica S.A.U., GnuBIO Inc., IMV Medical Information Division Inc., International Marketing Ventures Ltd., MJ GeneWorks, QuantaLife, Raindance Technologies Limited, Raindance Techologies Inc., Research Specialties for Laboratories NV, Respiratory Diagnostics Inc., and Wuxi BioCanal Nano Technology Co. Ltd..

When was Bio-Rad Laboratories founded?

Bio-Rad Laboratories was founded in 1952.

What is Bio-Rad Laboratories' official website?

The official website for Bio-Rad Laboratories is www.bio-rad.com.

Where are Bio-Rad Laboratories' headquarters?

Bio-Rad Laboratories is headquartered at 1000 ALFRED NOBEL DRIVE, HERCULES CA, 94547.

How can I contact Bio-Rad Laboratories?

Bio-Rad Laboratories' mailing address is 1000 ALFRED NOBEL DRIVE, HERCULES CA, 94547. The medical research company can be reached via phone at (510) 724-7000 or via email at [email protected].


This page was last updated on 9/25/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.